First Telix and Duchembio Joint Symposium – Emergence of PSMA-PET Imaging in South Korea
With our partner, Duchembio, we are pleased to present a first joint symposium on 68Ga-PSMA-PET prostate cancer imaging in…
Read moreNews & Views
NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed
Telix is pleased to announce that the first Australian patient has been dosed in the international NOBLE Registry, a global study that aims to improve access for men to state-of-the-art…
Read more
ZIRCON Presentation at International Kidney Cancer Symposium 2021
Telix is pleased to release a poster on the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab), the Company’s investigational imaging agent for clear cell renal cell carcinoma (ccRCC) with positron…
Read more
Australian TGA Approves Illuccix® for Prostate Cancer Imaging
Australian Therapeutic Goods Administration has approved Illuccix® for the diagnostic imaging of men with prostate…
Read more
Telix Japan – Upcoming Events in November
We are pleased to announce Telix’s participation at three major industry events in Japan during November 2021….
Read more
Activities Report and Appendix 4C for September 2021 Quarter
Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September…
Read more
IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting
Telix presented the IPAX-1 study of TLX101 in glioblastoma at the Congress of Neurological Surgeons Annual…
Read more
Telix Satellite Symposium at European Association of Nuclear Medicine Annual Congress 2021
Telix is pleased to announce a satellite symposium at the 34th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held from 20-23 October 2021….
Read more
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
Telix is pleased to announce that a first patient has been dosed in a Phase II study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with triple-negative breast cancer (TNBC) at the Institut…
Read more
Telix Establishes Commercial Hub in Geneva, Switzerland
Telix is pleased to announce that it has established a new commercial hub in Geneva through its subsidiary, Telix Pharmaceuticals (Switzerland)…
Read more